TAK

Takeda Pharm

• TipRanks·19h ago

  Spyre Therapeutics price target raised to $80 from $65 at Wedbush

• Seeking Alpha·22h ago

  My Top 4 Pharma Picks Under Rising Geopolitical Risk

• Reuters·1d ago

  Spyre's inflammatory bowel drug reduces disease activity in mid-stage study

• TipRanks·3d ago

  Takeda Updates Early-Stage Multiple Myeloma Study for TAK-079, Signaling Ongoing Oncology Push

• TipRanks·6d ago

  Takeda upgraded to Outperform from Market Perform at Bernstein

• Benzinga·04/06 17:26

  Takeda Exits Dementia Drug Partnership With Denali Therapeutics - Here's Why

• Reuters·04/06 15:57

  BUZZ-Denali slips as Takeda exits dementia drug partnership

• Reuters·04/06 10:21

  Takeda files Form 3 for Chief Human Resources Officer Nicola Greenway

• Reuters·04/06 10:19

  Takeda files initial beneficial ownership statement for Chief Medical Officer Awny Farajallah

• Reuters·04/06 10:17

  Takeda files Form 3 for President, PDT BU Ramy Ibrahim

• Benzinga·04/06 07:03

  Reported Friday, Denali Therapeutics Regains Full Rights To DNL593 After Takeda Terminates Collaboration, Phase 1/2 FTD-GRN Trial Results Expected By End Of 2026

• TipRanks·04/06 01:15

  Denali Therapeutics regains full rights to DNL593

• Dow Jones·04/03 17:49

  Takeda Ends Denali Therapeutics Dementia-Drug Partnership

• Reuters·04/03 17:35

  Denali regains full rights to DNL593 after Takeda ends collaboration

• Reuters·04/03 17:30

  DENALI THERAPEUTICS INC - RESULTS FROM PHASE 1/2 STUDY IN FTD-GRN EXPECTED BY END OF 2026